Targeting PARP-1 has shown promise in overcoming resistance, as the combination of the DNA repair inhibitor ailanthone with a PARP-1 inhibitor synergistically suppresses tumor growth in gastric cancer [46]. The gene discussed is PARP1; the disease is neoplasm.